iberdomide
iberdomide: 16 clinical trials tracked.
iberdomide evidence translation
What we can confirm
16 tracked trials
What it means
What to watch
Prepared research question
What is verified about iberdomide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 3 study sponsors
Clinical Trial Registry Records (16)showing 10 most recent
Expanded Access for Iberdomide
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (NDMM)
Primary endpoint: 3-Year Sustained Minimal Residual Disease (sMRD)-negative Complete Response (CR) Rate [Cohort 1] (Step 2)
Feasibility Study of Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Primary endpoint: Proportion of patients with T cell effector memory (TEM) expansion following iberdomide priming.
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Phase 1: Dose-Limiting Toxicities (DLT)s of Etentamig when given in Combination with Iberdomide in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM
Primary endpoint: Number of Participants with Adverse Events (AE)s
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Primary endpoint: Treatment deliverability, measured by treatment discontinuation before completion of 26 cycles
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Primary endpoint: Maximum tolerated dose (MTD) of iberdomide (Phase I)
A Randomized Phase III Trial Assessing Iberdomide Versus Iberdomide Plus Isatuximab Maintenance Therapy Post Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Primary endpoint: Demonstration of superiority of iberdomide plus isatuximab compared to iberdomide with respect to bone marrow minimal residual disease (MRD).
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Primary endpoint: Incidence of adverse events (AEs)
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Primary endpoint: Part 1: Number of participants with dose limiting toxicity (DLT)